Evidence map›Paper›PMID 39982209›Full record

Trial reportClinical pharmacology and therapeutics2025

A Phenotyping Tool for Seven Cytochrome P450 Enzymes and Two Transporters: Application to Examine the Effects of Clopidogrel and Gemfibrozil.

Laura Aurinsalo, Outi Lapatto-Reiniluoto, Mika Kurkela, Mikko Neuvonen, Johanna I Kiiski, Mikko Niemi, Aleksi Tornio, Janne T Backman

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in Clinical pharmacology and therapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Laura AurinsaloDepartment of Clinical Pharmacology, University of Helsinki, Helsinki, Finland.ORCID 0000-0003-1915-6227
Outi Lapatto-ReiniluotoDepartment of Clinical Pharmacology, University of Helsinki, Helsinki, Finland.ORCID 0000-0003-2463-1862
Mika KurkelaDepartment of Clinical Pharmacology, University of Helsinki, Helsinki, Finland.ORCID 0000-0002-4153-4143
Mikko NeuvonenDepartment of Clinical Pharmacology, University of Helsinki, Helsinki, Finland.ORCID 0000-0002-7627-1638
Johanna I KiiskiDepartment of Clinical Pharmacology, University of Helsinki, Helsinki, Finland.ORCID 0000-0002-4089-7209
Mikko NiemiDepartment of Clinical Pharmacology, University of Helsinki, Helsinki, Finland.ORCID 0000-0003-4550-2189
Aleksi Tornio *Integrative Physiology and Pharmacology, Institute of Biomedicine, University of Turku, Turku, Finland.ORCID 0000-0001-5713-5692
Janne T Backman *Department of Clinical Pharmacology, University of Helsinki, Helsinki, Finland.ORCID 0000-0002-9577-2788

Funding

Academy of Finland 325667Finnish Medical Foundation 4697Hospital District of Helsinki and Uusimaa, FinlandSigrid Jusélius Foundation 8037State Funding for University-Level Health Research TYH2019300State Funding for University-Level Health Research TYH2021304
6 · The paper itself

Abstract

Clinical cocktails for cytochrome P450 (CYP) phenotyping lack a marker for CYP2C8. We aimed to combine the CYP2C8 index drug repaglinide with the Geneva cocktail (caffeine/CYP1A2, bupropion/CYP2B6, flurbiprofen/CYP2C9, omeprazole/CYP2C19, dextromethorphan/CYP2D6, and midazolam/CYP3A4). We also included endogenous organic anion transporting polypeptide (OATP) 1B1 and 1B3 biomarkers glycochenodeoxycholate 3-O-glucuronide and glycochenodeoxycholate 3-sulfate, and investigated the CYP2C8 inhibition selectivity of clopidogrel and gemfibrozil with the full cocktail. In a five-phase randomized cross-over study, the following drugs were administered to 16 healthy volunteers: (i) repaglinide, (ii) the Geneva cocktail, (iii) repaglinide with the Geneva cocktail (full cocktail), (iv) clopidogrel followed by the full cocktail, and (v) gemfibrozil followed by the full cocktail. The Geneva cocktail increased repaglinide AUC

Indexed as

ClopidogrelCytochrome P-450 CYP2C8 InhibitorsCytochrome P-450 Enzyme SystemGemfibrozilHypolipidemic AgentsAdultCarbamatesCross-Over StudiesCytochrome P-450 CYP2C8Drug InteractionsFemaleHealthy VolunteersHumansLiver-Specific Organic Anion Transporter 1MaleMiddle AgedCarbamatesClopidogrelCYP2C8 protein, humanCytochrome P-450 CYP2C8Cytochrome P-450 CYP2C8 InhibitorsCytochrome P-450 Enzyme SystemGemfibrozilHypolipidemic AgentsLiver-Specific Organic Anion Transporter 1PiperidinesPlatelet Aggregation InhibitorsrepaglinideSLCO1B1 protein, human

Identifiers

PMID39982209
PMCPMC12087695

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.